As of July 24, 2025, Daré Bioscience, Inc. has demonstrated compliance with Nasdaq's stockholders' equity requirement, thus meeting the continued listing requirements of the Nasdaq Capital Market. However, the company will be monitored for one year by a Mandatory Panel Monitor to ensure ongoing compliance. If Daré Bioscience falls out of compliance within this period, they will receive a delist determination letter and may request a new hearing with Nasdaq's Hearings Panel.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.